Prevenar 20 has become the pneumococcal vaccine that covers the most serotypes in Korea. Experts believe that its use will increase to address the unmet need for a treatment that protects against serotypes not targeted by existing vaccines.

Pfizer Korea held a press conference at the Lotte Hotel in Jung-gu, Seoul on the 19th to celebrate the approval of Prevenar 20 in South Korea. The Ministry of Food and Drug Safety approved Prevenar 20 as a new pneumococcal vaccine on March 31st.

With the approval, Prevenar 20 is now available for ▲ the prevention of invasive disease, pneumonia and acute otitis media caused by 20 Streptococcus pneumoniae strains (1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 1